In a fresh update, Bloomberg has reported that US biotech Amgen Inc. has agreed to purchase Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26bn), in a deal which could yet see ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining forces with Aptar to develop algorithms that can be used to detect CKD ...

A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer. The European Commission has cleared AZ's PD ...

Eli Lilly seems to have responded to the threat by President Donald Trump of tariffs on the pharma industry if they don't relocate their manufacturing operations to the US. The pharma group has ...

Artificial intelligence’s role in drug discovery is apparent and well-known, with start-ups like Deep Genomics and Atomwise commanding impressive funding rounds. While the advanced tech is ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) into pivotal testing.

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested outside ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

Not very long ago, contracting HIV was an effective death sentence; today, there are treatments that allow the condition to be managed but not eradicated. Ben Hargreaves outlines how research is ...

Even now, after a decade of run-up, pharma’s readiness to implement and harness ISO IDMP standards still varies wildly, as does companies’ relative maturity in supporting FAIR data principles ...